Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | WNT3A | P56704 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250713 | 0.80 | SIGMAR1 (0.45) | SLC2A1SIGMAR1 | |
| SCHEMBL3247818 | 0.79 | HDAC1 (0.34) | HDAC1HDAC8MEN1KMT2ASLC2A1 | |
| SCHEMBL3244602 | 0.77 | CYP1A2 (0.42) | SLC2A1 | |
| SCHEMBL3250810 | 0.76 | MEN1 (0.34) | HDAC1HDAC8MEN1KMT2AAR | |
| SCHEMBL1508252 | 0.74 | HDAC1 (0.48) | HDAC1HDAC8MEN1KMT2AAR | |
| SCHEMBL3242867 | 0.73 | SLC2A1 (0.56) | MEN1KMT2ASLC2A1 | |
| SCHEMBL3244852 | 0.73 | MTNR1A (0.44) | SIGMAR1 | |
| SCHEMBL3071084 | 0.72 | AR (0.36) | MEN1KMT2ACTNNB1WNT3AAR | |
| SCHEMBL27549726 | 0.72 | SLC2A1 (0.32) | SLC2A1 | |
| SCHEMBL7184372 | 0.72 | HPRT1 (0.42) | MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | HDAC1 90/4885HDAC8 321/4885MEN1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.